Lv2
130 积分 2024-09-13 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2天前
已完结
Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology
23天前
已完结
Design, synthesis, and structure-activity relationship study of novel GLP-1/GIP/GCG triple receptor agonists
1个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
1个月前
已完结
Adipose tissue ageing: implications for metabolic health and lifespan
2个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
4个月前
已完结
Semaglutide and Tirzepatide to Treat Obesity
4个月前
已完结
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
5个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
5个月前
已完结
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
6个月前
已完结
皖公网安备34019202002308
